Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01868126 · ClinicalTrials.gov registry record · Phase 2
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT01868126: Completed Phase 2 study, sponsored by Santen.
NCT01868126 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 91 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01868126, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
Primary Outcome
Intraocular pressure (mmHg) measurements will be collected at each visit using Goldmann applanation tonometry
Interventions
- OTHER Placebo
- DRUG DE-117 ophthalmic solution
- DRUG latanoprost ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01868126 record still lists
NCT01868126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01868126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01868126 about?
NCT01868126 is a clinical study titled "Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension". The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
What is the current status of trial NCT01868126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2013-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01868126?
The interventions under investigation include: Placebo (OTHER), DE-117 ophthalmic solution (DRUG), latanoprost ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01868126?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01868126's enrollment target sits among peer trials
91 771st of 2000 higher than 1,229 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia